Last October 2010, the Advisory Committee on Immunization Practices, American Academy of Family Physicians, American College of Obstetricians and Gynecologists, and the American College of Physicians approved the changes for the Adult Immunization Schedule for 2011.
Among the changes include the following:
1) recommendation for use of the tetanus, diphtheria, pertussis (Tdap) vaccine in adults aged 65 years or older
2)recommendation that Tdap can be administered regardless of how much time has elapsed since the last tetanus and diphtheria (Td)–containing vaccine
3) recommendation for a 2-dose series of meningococcal vaccine in adults with certain high-risk medical conditions.
There are also specific changes in the schedule for 2011 include the following:
- All persons at least 6 months old should be vaccinated against influenza
- Older persons (65 years old and above) who are in close contact with an infant younger than 12 months should receive tetanus, diphtheria, pertussis (Tdap) vaccine
- All persons at least 65 years old may also receive Tdap vaccine. Tdap should be administered regardless of time elapsed since receiving the last Td-containing vaccine.
- Vaccines against human papillomavirus (quadrivalent or bivalent) is recommended for girls and women.
- For revaccination with PPSV, 1-time revaccination after 5 years applies only to persons 19 through 64 years old with indicated chronic conditions, namely chronic renal failure or the nephrotic syndrome, functional or anatomic asplenia, or immunocompromising conditions.
- For adults with anatomic or functional asplenia or persistent complement component deficiencies and adults with HIV infection who are vaccinated with meningococcal conjugate vaccine (MCV4), a 2-dose series of meningococcal vaccine is recommended, with the 2 doses given 2 months apart. For those with other indications, a single dose of meningococcal vaccine is still recommended. Information in the new schedule clarifies that MCV4 is a quadrivalent vaccine.
- Information regarding the Hib vaccine clarifies which high-risk persons may receive 1 dose of Hib vaccine, namely persons who have sickle cell disease, leukemia, or HIV infection, or those who have had a splenectomy, if they have not previously received Hib vaccine.
Additional Schedule Highlights
Additional highlights of the Adult Immunization Schedule include the following:
- Adults younger than 65 years whose previous Td status is unknown should receive 1 dose of Tdap. Tdap should be administered immediately to postpartum women, close contacts of infants younger than 12 months, and healthcare workers.
- Girls 11 to 12 years old should receive HPV4 or HPV2. Catch-up vaccination in girls may be given until age 26 years. Boys and men 9 to 26 years old may be given HPV4 to lower their risk of acquiring genital warts.
- All persons at least 60 years old should receive a single dose of vaccine against herpes zoster, regardless of whether personal history is positive for herpes zoster.
- Recommendations for varicella vaccination are unchanged. Two vaccine doses at least 4 weeks apart should be given to all adults born during or after 1980 who have no evidence of immunity to varicella. Healthcare workers should not be considered to have immunity against varicella simply because of their age. Pregnant women should be evaluated for evidence of varicella immunity, and those lacking such evidence should receive the first dose of varicella vaccine on completion or termination of pregnancy and before discharge from the healthcare facility. The second dose should be given 4 to 8 weeks after the first dose.
- Hepatitis A vaccination should be given to anyone seeking protection from hepatitis A virus (HAV) infection, men who have sex with men, users of injection drugs, persons working with HAV-infected primates or with HAV in a research laboratory setting, persons with chronic liver disease and persons who receive clotting factor concentrates, and persons traveling to or working in countries with high or intermediate endemicity of hepatitis A.
- Hepatitis B vaccination should be given to anyone seeking protection from hepatitis B virus (HBV) infection, persons with more than 1 sex partner during the previous 6 months, persons seeking evaluation or treatment of a sexually transmitted disease, current or recent injection-drug users, men who have sex with men, healthcare personnel and public safety workers exposed to blood or other potentially infectious body fluids, persons with end-stage renal disease, persons with HIV infection, persons with chronic liver disease, household contacts and sex partners of persons with chronic HBV infection, clients and staff members of institutions for persons with developmental disabilities, and international travelers to countries with a high or intermediate prevalence of chronic HBV infection.
Source: MedScape News